Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in rod photoreceptor cells | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16912
Sealed predictions
- LMTK3 in dopamine neurons, braak-0.39 (p 0.299) → -0.34 (p 0.373)receipt 16918
Swarm cases
receipt 16918: LMTK3 in dopamine neurons, braak
- power
- full sample -0.32 (p 0.194, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.32 (p 0.191, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.093, n 18). could be the mix.
- skeptic
- leave-one-out range -0.42 to -0.24, sign flips 0; without severely affected donors -0.32 (p 0.194, n 18). fragile.
- cell type
- strongest in astrocytes: -0.59 (p 0.0099, n 18) vs -0.32 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LMTK3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LMTK3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.43 p 0.131 (needs p < 1.4e-4)
Receipts
loading the receipts